New hope for Crohn's patients when first drug fails
NCT ID NCT07487480
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a drug called guselkumab can help people with moderate to severe Crohn's disease who did not improve or could not tolerate another drug called ustekinumab. About 60 adults will receive guselkumab and be followed for 52 weeks. The main goal is to see how many achieve remission (fewer symptoms) by the end of the study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center of Inflammatory Bowel Disease, Department of Gastroenterology, the Second Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310009, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a patient registry unlock the secrets of IBD?
- Can we predict how kids with IBD will respond to treatment?
- Can switching IBD meds heal the gut when symptoms are quiet?
- Can a milk sugar tame IBD symptoms?
- Could an extra flu shot shield vulnerable kids?
- Can a Real-World study reveal the staying power of guselkumab?